MX2016002795A - Compuestos de triazolona y usos de los mismos. - Google Patents
Compuestos de triazolona y usos de los mismos.Info
- Publication number
- MX2016002795A MX2016002795A MX2016002795A MX2016002795A MX2016002795A MX 2016002795 A MX2016002795 A MX 2016002795A MX 2016002795 A MX2016002795 A MX 2016002795A MX 2016002795 A MX2016002795 A MX 2016002795A MX 2016002795 A MX2016002795 A MX 2016002795A
- Authority
- MX
- Mexico
- Prior art keywords
- pparî
- cancers
- directed
- invention disclosed
- melanoma
- Prior art date
Links
- FFSJPOPLSWBGQY-UHFFFAOYSA-N triazol-4-one Chemical class O=C1C=NN=N1 FFSJPOPLSWBGQY-UHFFFAOYSA-N 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 4
- 210000000481 breast Anatomy 0.000 abstract 3
- 210000001072 colon Anatomy 0.000 abstract 3
- 201000001441 melanoma Diseases 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 3
- 210000002307 prostate Anatomy 0.000 abstract 3
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 abstract 2
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 abstract 2
- 239000005557 antagonist Substances 0.000 abstract 2
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 abstract 2
- 230000009977 dual effect Effects 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 abstract 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 abstract 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 abstract 1
- 208000031886 HIV Infections Diseases 0.000 abstract 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 abstract 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 abstract 1
- 208000036142 Viral infection Diseases 0.000 abstract 1
- 230000001154 acute effect Effects 0.000 abstract 1
- 230000001684 chronic effect Effects 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 210000003734 kidney Anatomy 0.000 abstract 1
- 208000032839 leukemia Diseases 0.000 abstract 1
- 210000004185 liver Anatomy 0.000 abstract 1
- 230000002611 ovarian Effects 0.000 abstract 1
- 230000009385 viral infection Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
- C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D249/12—Oxygen or sulfur atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Gastroenterology & Hepatology (AREA)
- AIDS & HIV (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
[000180] La invención descrita en la presente se refiere a compuestos de las Fórmulas Ia y Ib (ver Fórmula) y sales farmacéuticamente aceptables de estos, que son útiles en el tratamiento de cánceres de próstata, mama, colon, pancreático, leucemia linfocítica crónica humana, melanoma y otros. La invención también comprende composiciones farmacéuticas que comprenden una cantidad terapéuticamente efectiva del compuesto de la Fórmula Ia o Ib, o una sal farmacéuticamente aceptable del mismo. La invención descrita en la presente también se refiere a métodos para tratar cánceres de próstata, mama, ovario, hígado, riñón, colon, pancreático, leucemia linfocítica crónica humana, melanoma y otros cánceres. La invención descrita en la presente se refiere adicionalmente a métodos para tratar cánceres de próstata, mama, ovario, hígado, riñón, colon, pancreático, leucemia linfocítica crónica humana, melanoma y otros cánceres, que comprenden la administración de una cantidad terapéuticamente efectiva de un compuesto que es un antagonista dual tanto de PPARa como de PPARd. Los compuestos y composiciones farmacéuticas de la invención también son útiles en el tratamiento de infecciones virales, tal como infecciones por HCV e infecciones por VIH. La invención descrita en la presente también se refiere a métodos para impedir el comienzo de y/o recurrencia de leucemia mieloide aguda o crónica, así como otros cánceres, que comprende la administración de una cantidad terapéuticamente efectiva de un antagonista dual tanto de PPARa como de PPARd.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361874956P | 2013-09-06 | 2013-09-06 | |
| PCT/US2014/054108 WO2015035059A1 (en) | 2013-09-06 | 2014-09-04 | Triazolone compounds and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2016002795A true MX2016002795A (es) | 2016-05-26 |
Family
ID=52628929
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2016002795A MX2016002795A (es) | 2013-09-06 | 2014-09-04 | Compuestos de triazolona y usos de los mismos. |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US9776976B2 (es) |
| EP (1) | EP3041826A4 (es) |
| JP (1) | JP2016529311A (es) |
| KR (1) | KR20160048988A (es) |
| CN (1) | CN105579440A (es) |
| AU (1) | AU2014315151A1 (es) |
| CA (1) | CA2921420A1 (es) |
| EA (1) | EA201690230A1 (es) |
| IL (1) | IL244383A0 (es) |
| MX (1) | MX2016002795A (es) |
| PE (1) | PE20160880A1 (es) |
| SG (1) | SG11201601066VA (es) |
| WO (1) | WO2015035059A1 (es) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2935228T3 (en) | 2012-12-20 | 2017-10-30 | Inception 2 Inc | TRIAZOLONE COMPOUNDS AND APPLICATIONS THEREOF |
| US10421756B2 (en) | 2015-07-06 | 2019-09-24 | Rodin Therapeutics, Inc. | Heterobicyclic N-aminophenyl-amides as inhibitors of histone deacetylase |
| HRP20211864T1 (hr) | 2015-07-06 | 2022-03-04 | Alkermes, Inc. | Inhibitori hetero-halo histonske deacetilaze |
| AU2017295745A1 (en) | 2016-07-12 | 2019-01-31 | Bayer Cropscience Aktiengesellschaft | Bicyclic compounds as pest control agents |
| HRP20220223T1 (hr) | 2017-01-11 | 2022-04-29 | Alkermes, Inc. | Biciklički inhibitori histon deacetilaze |
| PL3664802T3 (pl) | 2017-08-07 | 2022-07-11 | Alkermes, Inc. | Bicykliczne inhibitory deacetylaz histonowych |
| CN112168820B (zh) * | 2019-07-05 | 2023-09-29 | 中国科学院生物物理研究所 | SRCAP ATPase抑制剂在结直肠癌治疗中的应用 |
| GB201910037D0 (en) | 2019-07-12 | 2019-08-28 | Syngenta Crop Protection Ag | Microbiocidal compounds |
| CN114853686B (zh) * | 2021-08-23 | 2023-06-20 | 中国药科大学 | 三氮唑酮类化合物及其医药用途 |
| CN115894379B (zh) * | 2022-01-20 | 2025-06-27 | 哈尔滨三联药业股份有限公司 | 海因类化合物及其医药用途 |
Family Cites Families (133)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI76795C (fi) | 1979-09-04 | 1988-12-12 | Bristol Myers Co | Foerfarande foer framstaellning av nya, terapeutiskt anvaendbara 3,4-disubstituerade 1,2,5-tiadiazol-1-oxider och -1,1-dioxider samt nya mellanprodukter. |
| US4487773A (en) | 1981-03-16 | 1984-12-11 | Mead Johnson & Company | 1,2,4-Triazol-3-one antidepressants |
| IN158869B (es) | 1981-03-18 | 1987-02-07 | Ici Plc | |
| DD160447A1 (de) | 1981-03-26 | 1983-08-03 | Johannes Dost | Herbizide mittel, die 1,2,4-triazolinone-(5) enthalten |
| DE3267110D1 (de) | 1981-05-18 | 1985-12-05 | Ici Plc | Amidine derivatives |
| DE3238590A1 (de) | 1982-10-19 | 1984-04-19 | VEB Fahlberg-List Chemische und pharmazeutische Fabriken, DDR 3013 Magdeburg | Herbizide mittel, die 1,2,4-triazolinone-(5) enthalten |
| NL8204109A (nl) | 1982-10-25 | 1984-05-16 | Fahlberg List Veb | Herbicide middelen, die 1.2.4-triazolinon-(5)-verbindingen bevatten. |
| FR2535168B1 (fr) | 1982-10-29 | 1985-08-09 | Fahlberg List Veb | Agents herbicides a base de 1, 2, 4-triazolinone 5 |
| JPS60215675A (ja) | 1984-04-09 | 1985-10-29 | Nippon Nohyaku Co Ltd | オキサジアゾリノン誘導体及びトリアゾリノン誘導体並びにその製造方法並びに昆虫成長制御剤 |
| PH24094A (en) | 1986-12-19 | 1990-03-05 | Merrell Dow Pharma | 5-aryl-3h-1,2,4-triazol-3-ones and their use as anticonvulsants |
| DE3934081A1 (de) | 1989-10-12 | 1991-04-18 | Bayer Ag | Sulfonylaminocarbonyltriazolinone |
| EP0500864B1 (en) | 1990-09-06 | 2001-09-19 | Pfizer Limited | Antimuscarinic bronchodilators |
| JP2772875B2 (ja) | 1991-05-14 | 1998-07-09 | 富士写真フイルム株式会社 | ハロゲン化銀カラー写真感光材料の処理方法及び写真用漂白定着組成物 |
| EP0612314B1 (en) | 1991-10-30 | 1999-12-29 | Astra Aktiebolag | 2-pyrazinylethylamine derivatives and their use as pharmaceuticals |
| EP0636130A1 (en) | 1992-04-15 | 1995-02-01 | Merck Sharp & Dohme Ltd. | Azacyclic compounds |
| DE4224929A1 (de) | 1992-07-28 | 1994-02-03 | Bayer Ag | Heterocyclyltriazolinone |
| US5284957A (en) | 1992-09-03 | 1994-02-08 | Eli Lilly And Company | Excitatory amino acid receptor antagonists |
| IT1256387B (it) | 1992-11-13 | 1995-12-04 | Acraf | Procedimento per preparare triazoloni |
| US5783593A (en) | 1993-11-04 | 1998-07-21 | Abbott Laboratories | Inhibitors of squalene synthetase and protein farnesyltransferase |
| DE4343595A1 (de) | 1993-12-21 | 1995-06-22 | Bayer Ag | Verfahren zur Herstellung von Sulfonylaminocarbonyltriazolinonen |
| US5550118A (en) | 1994-01-31 | 1996-08-27 | Eli Lilly And Company | Polyhydronorharman synthase inhibitors |
| DE4404848A1 (de) | 1994-02-16 | 1995-08-17 | Hoechst Ag | Substituierte Cyclohexanolester, ihre Verwendung zur Behandlung von Krankheiten und pharmazeutische Präparate |
| US5464788A (en) | 1994-03-24 | 1995-11-07 | Merck & Co., Inc. | Tocolytic oxytocin receptor antagonists |
| GB9418545D0 (en) | 1994-09-15 | 1994-11-02 | Merck Sharp & Dohme | Therapeutic agents |
| JPH08157473A (ja) | 1994-10-06 | 1996-06-18 | Nissan Chem Ind Ltd | ピラゾール系チアゾリジン類 |
| US5641796A (en) | 1994-11-01 | 1997-06-24 | Eli Lilly And Company | Oral hypoglycemic agents |
| IN183333B (es) | 1995-03-15 | 1999-11-20 | Indian Drugs & Pharma | |
| IL118325A0 (en) | 1995-05-25 | 1996-10-31 | Pont Merck And Pharmaceutical | Integrin receptor antagonists and pharmaceutical compositions containing them |
| DE19521162A1 (de) | 1995-06-09 | 1996-12-12 | Bayer Ag | N-Aryl-1,2,4-triazolin-5-one |
| GB9513117D0 (en) | 1995-06-28 | 1995-08-30 | Merck Sharp & Dohme | Therapeutic agents |
| GB9513121D0 (en) | 1995-06-28 | 1995-08-30 | Merck Sharp & Dohme | Therapeutic agents |
| EP0784053A1 (de) | 1996-01-15 | 1997-07-16 | Degussa Aktiengesellschaft | Verfahren zur Herstellung von Triazolinonherbiziden |
| DE19601189A1 (de) | 1996-01-15 | 1997-07-17 | Degussa | Verfahren zur Herstellung von 1,2,4-Triazolin-3(2H)-onen |
| AU2381397A (en) | 1996-04-19 | 1997-11-12 | Novo Nordisk A/S | Modulators of molecules with phosphotyrosine recognition units |
| TW467902B (en) | 1996-07-31 | 2001-12-11 | Bristol Myers Squibb Co | Diphenyl heterocycles as potassium channel modulators |
| AU726745B2 (en) | 1996-10-07 | 2000-11-16 | Merck Sharp & Dohme Limited | CNS-penetrant NK-1 receptor antagonists as antidepressant and/or an anti-anxiety agent |
| WO1998018496A2 (en) | 1996-10-28 | 1998-05-07 | Nycomed Imaging As | Contrast agents |
| WO1998043962A1 (en) | 1997-03-28 | 1998-10-08 | Du Pont Pharmaceuticals Company | Heterocyclic integrin inhibitor prodrugs |
| AU8242598A (en) | 1997-07-18 | 1999-02-10 | Nippon Kayaku Kabushiki Kaisha | Aromatic ketone derivatives and uses thereof |
| WO1999026945A1 (en) | 1997-11-26 | 1999-06-03 | Du Pont Pharmaceuticals Company | 1,3,4-THIADIAZOLES AND 1,3,4-OXADIAZOLES AS αvβ3 ANTAGONISTS |
| US6331537B1 (en) | 1998-06-03 | 2001-12-18 | Gpi Nil Holdings, Inc. | Carboxylic acids and carboxylic acid isosteres of N-heterocyclic compounds |
| IL140041A0 (en) | 1998-06-03 | 2002-02-10 | Guilford Pharm Inc | Multiple heteroatom containing heterocyclic ring compounds substituted with carboxylic acids and isosteres thereof |
| KR20010052503A (ko) | 1998-06-03 | 2001-06-25 | 다니엘 피. 맥컬럼 | Ｎ-헤테로사이클릭 카복실산 또는 카복실산 등입체의ｎ-결합된 설폰아미드 |
| US7265150B1 (en) | 1998-08-14 | 2007-09-04 | Gpi Nil Holdings Inc. | Carboxylic acids and carboxylic acid isosteres of N-heterocyclic compounds for vision and memory disorders |
| AU5477899A (en) | 1998-08-14 | 2000-03-06 | Gpi Nil Holdings, Inc. | Ureas and carbamates of N-heterocyclic carboxylic acids and isosteres for vision and memory disorders |
| US6339101B1 (en) | 1998-08-14 | 2002-01-15 | Gpi Nil Holdings, Inc. | N-linked sulfonamides of N-heterocyclic carboxylic acids or isosteres for vision and memory disorders |
| SE9802937D0 (sv) | 1998-09-01 | 1998-09-01 | Astra Pharma Prod | Novel compounds |
| AU1345600A (en) | 1998-11-12 | 2000-06-05 | Merck & Co., Inc. | Pyrimidinedione derivatives useful as alpha 1a adrenoceptor antagonists |
| FR2793791B1 (fr) | 1999-05-19 | 2002-01-25 | Univ Paris 7 Denis Diderot | Nouveaux composes inhibiteurs specifiques de phospholipases a2 |
| DE19955662B4 (de) | 1999-11-19 | 2011-03-31 | Arysta LifeScience North America, | Herbizide auf Basis von Carbamoyltriazolinon |
| EP1110958A1 (en) | 1999-12-20 | 2001-06-27 | Ucb, S.A. | Alpha-arylethylpiperazine derivatives as neurokinin antagonists |
| AU6594401A (en) | 2000-05-24 | 2001-12-03 | Bayer Aktiengesellschaft | 6-heterocyclyl-3-oxo-3,4-dihydro-quinoxalines |
| US6465456B2 (en) | 2000-06-29 | 2002-10-15 | Bristol-Myers Squibb Company | Isoxazolinone antibacterial agents |
| JO2654B1 (en) | 2000-09-04 | 2012-06-17 | شركة جانسين فارماسوتيكا ان. في | Multiple aryl caroxa amides are useful as lipid - lowering agents |
| US6576644B2 (en) | 2000-09-06 | 2003-06-10 | Bristol-Myers Squibb Co. | Quinoline inhibitors of cGMP phosphodiesterase |
| UA82048C2 (uk) * | 2000-11-10 | 2008-03-11 | Эли Лилли Энд Компани | Агоністи альфа-рецепторів, активованих проліфератором пероксисом |
| CA2450555A1 (en) | 2001-06-25 | 2003-01-03 | Merck & Co., Inc. | (pyrimidyl)(phenyl)substituted fused heteroaryl p38 inhibiting and pkg kinase inhibiting compounds |
| ATE374194T1 (de) | 2001-12-18 | 2007-10-15 | Merck & Co Inc | Heteroarylsubstituierte triazolmodulatoren des metabotropen glutamatarezeptors 5 |
| ATE403426T1 (de) | 2002-02-07 | 2008-08-15 | Univ Missouri | Opioid-rezeptor-aktive 4-(3-hydroxyphenyl) oder 4-(3-alkoxyphenyl)-1,2,4-triazol-verbindungen |
| US6995144B2 (en) | 2002-03-14 | 2006-02-07 | Eisai Co., Ltd. | Nitrogen containing heterocyclic compounds and medicines containing the same |
| US20050256003A1 (en) | 2002-06-14 | 2005-11-17 | Christoph Luthy | Novel herbicides |
| AU2003284001A1 (en) | 2002-10-07 | 2004-05-04 | Bristol-Myers Squibb Company | Triazolone and triazolethione derivatives |
| PL375889A1 (en) | 2002-10-11 | 2005-12-12 | Cytokinetics, Inc. | Compounds for treating cellular proliferative diseases, compositions containing them and their application |
| EP1558589A4 (en) | 2002-10-11 | 2008-01-09 | Cytokinetics Inc | COMPOUNDS, COMPOSITIONS AND METHODS |
| TW200423930A (en) | 2003-02-18 | 2004-11-16 | Hoffmann La Roche | Non-nucleoside reverse transcriptase inhibitors |
| WO2004089306A2 (en) | 2003-04-04 | 2004-10-21 | Merck & Co., Inc. | Di-aryl substituted triazole modulators of metabotropic glutamate receptor-5 |
| ES2338656T3 (es) | 2003-04-11 | 2010-05-11 | High Point Pharmaceuticals, Llc | Uso farmaceutico de 1,2,4-triazoles fusionados. |
| UA89035C2 (ru) | 2003-12-03 | 2009-12-25 | Лео Фарма А/С | Эфиры гидроксамовых кислот и их фармацевтическое применение |
| US7605171B2 (en) | 2003-12-17 | 2009-10-20 | Merck & Co., Inc. | (3,4-disubstituted)propanoic carboxylates as S1P (Edg) receptor agonists |
| WO2005077345A1 (en) | 2004-02-03 | 2005-08-25 | Astrazeneca Ab | Compounds for the treatment of gastro-esophageal reflux disease |
| WO2005077178A2 (en) | 2004-02-16 | 2005-08-25 | Syngenta Participations Ag | Herbicidal composition |
| TW200604183A (en) | 2004-02-18 | 2006-02-01 | Astrazeneca Ab | Triazole compounds and their use as metabotropic glutamate receptor antagonists |
| SE0400850D0 (sv) | 2004-03-30 | 2004-03-31 | Astrazeneca Ab | Novel Compounds |
| CN1993332B (zh) | 2004-07-27 | 2011-04-06 | 弗·哈夫曼-拉罗切有限公司 | 作为非核苷逆转录酶抑制剂的苄基三唑酮化合物 |
| CN1315810C (zh) | 2004-08-30 | 2007-05-16 | 北京理工大学 | 哌嗪桥联他克林双体衍生物及其合成方法 |
| GT200500284A (es) | 2004-10-15 | 2006-03-27 | Aventis Pharma Inc | Pirimidinas como antagonistas del receptor de prostaglandina d2 |
| AU2005299851B2 (en) | 2004-10-22 | 2011-03-17 | Merck Sharp & Dohme Corp. | 2-(aryl)azacyclylmethyl carboxylates, sulfonates, phosphonates, phosphinates and heterocycles as S1P receptor agonists |
| WO2006068199A1 (ja) | 2004-12-22 | 2006-06-29 | Mochida Pharmaceutical Co., Ltd. | 代謝的に安定な３－オキシ－１，２，４－トリアゾール誘導体 |
| EP1844048B1 (en) | 2005-01-14 | 2010-05-26 | Janssen Pharmaceutica N.V. | Pyrazolopyrimidines as cell cycle kinase inhibitors |
| WO2006078698A1 (en) | 2005-01-19 | 2006-07-27 | Cengent Therapeutics, Inc. | 2-imidazolone and 2-imidazolidinone heterocyclic inhibitors of tyrosine phosphatases |
| PE20061041A1 (es) | 2005-01-28 | 2006-10-12 | Lilly Co Eli | Formulaciones y regimen de dosificacion para moduladores alfa de ppar |
| WO2006109056A1 (en) | 2005-04-12 | 2006-10-19 | Vicore Pharma Ab | New tricyclic angiotensin ii agonists |
| DE112006001089B4 (de) | 2005-04-28 | 2015-05-28 | Denso Corporation | Mehrphasiger bürstenloser Elektromotor |
| DE102005025992A1 (de) | 2005-06-07 | 2007-01-11 | Lanxess Deutschland Gmbh | Verfahren zur Herstellung von substituierten Azolen |
| US20070032488A1 (en) | 2005-08-05 | 2007-02-08 | Genelabs Technologies, Inc. | 6-Membered aryl and heteroaryl derivatives for treating viruses |
| BRPI0617948A2 (pt) | 2005-10-28 | 2011-08-09 | Takeda Pharmaceutical | composto, pró-droga de um composto, agente farmacêutico, método para inibir uma metaloproteinase de matriz, e, uso de um composto |
| KR20080080584A (ko) | 2005-11-30 | 2008-09-04 | 버텍스 파마슈티칼스 인코포레이티드 | ｃ-Ｍｅｔ의 억제제 및 이의 용도 |
| DE102006003444A1 (de) | 2006-01-25 | 2007-07-26 | Lanxess Deutschland Gmbh | Verfahren zur Herstellung von iodierten Azolen |
| GB2435827A (en) | 2006-03-09 | 2007-09-12 | Del Dr Esteve S A Spain Lab | Use of substituted piperazine compounds for the treatment of food related disorders |
| GB2435829A (en) | 2006-03-09 | 2007-09-12 | Del Dr Esteve S A Spain Lab | Pyrimidinyl-2-piperazine compounds for use in disorders related to food intake |
| GB2435828A (en) | 2006-03-09 | 2007-09-12 | Del Dr Esteve S A Spain Lab | Use of substituted phenyl-piperazine compounds for treatment of food related disorders |
| US7674811B2 (en) | 2006-03-14 | 2010-03-09 | Ranbaxy Laboratories Limited | 5-lipoxygenase inhibitors |
| US8088791B2 (en) | 2006-03-23 | 2012-01-03 | Biots Scientific Management Pty Ltd | Antibacterial agents |
| PT2000465E (pt) | 2006-03-24 | 2011-02-10 | Eisai R&D Man Co Ltd | Derivado de triazolona |
| DE102006023337A1 (de) | 2006-05-18 | 2007-11-22 | Merck Patent Gmbh | Triazolderivate II |
| WO2007139955A2 (en) | 2006-05-25 | 2007-12-06 | Synta Pharmaceuticals Corp. | Triazole compounds that modulate hsp90 activity |
| DE102006032164A1 (de) | 2006-07-12 | 2008-01-24 | Bayer Cropscience Ag | Substituierte Furyl-sulfonylamino(thio)carbonyl-triazolin(thi)one |
| US7994321B2 (en) | 2006-08-08 | 2011-08-09 | Hoffmann-La Roche Inc. | Substituted thieno[3,2-C]pyridine-7-carboxylic acid derivatives |
| KR20130036080A (ko) | 2006-08-15 | 2013-04-09 | 제논 파마슈티칼스 인크. | 증가된 지질 수준과 관련된 질환의 치료에 적합한 헤테로시클릭 화합물 |
| EA200970793A1 (ru) | 2007-02-23 | 2010-02-26 | Эли Лилли Энд Компани | Модуляторы рецепторов, активируемых пролифераторами пероксисом |
| CN101657433A (zh) | 2007-03-29 | 2010-02-24 | 弗·哈夫曼-拉罗切有限公司 | 非核苷逆转录酶抑制剂 |
| US20100120784A1 (en) | 2007-04-20 | 2010-05-13 | Lachance Nicolas | Novel heteroaromatic compounds as inhibitors of stearoyl-coenzyme a delta-9 desaturase |
| CA2685962A1 (en) | 2007-05-08 | 2009-02-05 | Burnham Institute For Medical Research | Tissue non-specific alkaline phosphatase inhibitors and uses thereof for treating vascular calcification |
| ES2617305T3 (es) | 2007-07-17 | 2017-06-16 | Acea Biosciences, Inc. | Compuestos heterocíclicos y usos como agentes anticancerosos |
| WO2009014910A2 (en) | 2007-07-19 | 2009-01-29 | Metabolex, Inc. | N-azacyclic substituted pyrrole, pyrazole, imidazole, triazole and tetrazole derivatives as agonists of the rup3 or gpr119 receptor for the treatment of diabetes and metabolic disorders |
| JP5358571B2 (ja) | 2007-08-07 | 2013-12-04 | プロサリク リミテッド | セロトニン作動性調節因子としての１，２，４−トリアゾール誘導体 |
| EP2215065B1 (en) | 2007-10-19 | 2012-07-11 | Boehringer Ingelheim International GmbH | Ccr10 antagonists |
| NZ585704A (en) | 2007-12-10 | 2012-08-31 | 7Tm Pharma As | Modulators of cannabinoid receptor CB1 for treating obesity |
| US20090281089A1 (en) | 2008-04-11 | 2009-11-12 | Genentech, Inc. | Pyridyl inhibitors of hedgehog signalling |
| HUE025984T2 (hu) | 2008-05-14 | 2016-05-30 | Scripps Research Inst | Szfingozin foszfát receptor új modulátorai |
| EP2310371B1 (fr) | 2008-05-26 | 2013-05-15 | Genfit | Composés agonistes ppar, préparation et utilisations pour le traitement du diabète et/ou des dyslipidémies |
| CN101643451B (zh) | 2008-08-07 | 2013-03-06 | 浙江海正药业股份有限公司 | 过氧化物酶增殖物激活受体亚型δ类激动剂化合物及其制备方法 |
| JP2011231015A (ja) | 2008-08-29 | 2011-11-17 | Taiho Yakuhin Kogyo Kk | 含窒素複素環を有する新規ウラシル化合物又はその塩 |
| CN102186825A (zh) | 2008-10-21 | 2011-09-14 | 麦它波莱克斯股份有限公司 | 芳基gpr120受体激动剂和其用途 |
| KR101220182B1 (ko) | 2009-02-25 | 2013-01-11 | 에스케이바이오팜 주식회사 | 치환된 아졸 유도체 화합물, 이를 포함하는 약제학적 조성물 및 이를 이용한 파킨슨씨 병 치료방법 |
| US8883827B2 (en) | 2009-06-05 | 2014-11-11 | Oslo University Hospital Hf | Azole derivatives as WTN pathway inhibitors |
| US20100331397A1 (en) | 2009-06-24 | 2010-12-30 | Alios Biopharma, Inc. | 2-5a analogs and their methods of use |
| DE102009028929A1 (de) | 2009-08-27 | 2011-07-07 | Bayer Schering Pharma Aktiengesellschaft, 13353 | Heterocyclisch-substituierte 2-Acetamido-5-Aryl-1,2,4-triazolone und deren Verwendung |
| WO2011058478A1 (en) | 2009-11-16 | 2011-05-19 | Pfizer Inc. | Substituted triazolopyrimidines as pde8 inhibitors |
| US20130022629A1 (en) | 2010-01-04 | 2013-01-24 | Sharpe Arlene H | Modulators of Immunoinhibitory Receptor PD-1, and Methods of Use Thereof |
| KR101169359B1 (ko) | 2010-01-29 | 2012-07-30 | 주식회사 레고켐 바이오사이언스 | 사이클릭 아미드라존 기를 가지는 신규한 옥사졸리디논 유도체 및 이를 함유하는 의약 조성물 |
| US8802864B2 (en) | 2010-02-22 | 2014-08-12 | Glaxosmithkline Llc | Triazolones as fatty acid synthase inhibitors |
| WO2011107530A2 (en) | 2010-03-03 | 2011-09-09 | Probiodrug Ag | Novel inhibitors |
| CN110269856A (zh) | 2010-03-30 | 2019-09-24 | 维颂公司 | 多取代芳族化合物作为凝血酶的抑制剂 |
| EP2371823A1 (de) | 2010-04-01 | 2011-10-05 | Bayer CropScience AG | Cyclopropyl-substituierte Phenylsulfonylamino(thio)carbonyltriazolinone, ihre Herstellung und Verwendung als Herbizide und Pflanzenwachstumsregulatoren |
| US8097634B2 (en) | 2010-04-15 | 2012-01-17 | Hoffmann-La Roche Inc. | Azacyclic derivatives |
| MY188960A (en) | 2010-08-10 | 2022-01-14 | Melinta Therapeutics Llc | Cyclic boronic acid ester derivatives and therapeutic uses thereof |
| US20130158063A1 (en) * | 2010-08-24 | 2013-06-20 | Georgetown University | Compounds, Compositions and Methods Related to PPAR Antagonists |
| EP2616071A2 (en) | 2010-09-17 | 2013-07-24 | GlaxoSmithKline Intellectual Property Development Limited | Fatty acid synthase inhibitors |
| JP5847533B2 (ja) | 2010-10-19 | 2016-01-27 | 田辺三菱製薬株式会社 | 新規甲状腺ホルモンβ受容体作動薬 |
| WO2012058531A2 (en) | 2010-10-29 | 2012-05-03 | North Carolina State University | Modulation of response regulators by imidazole derivatives |
| WO2013134562A1 (en) | 2012-03-09 | 2013-09-12 | Inception 2, Inc. | Triazolone compounds and uses thereof |
| DK2935228T3 (en) * | 2012-12-20 | 2017-10-30 | Inception 2 Inc | TRIAZOLONE COMPOUNDS AND APPLICATIONS THEREOF |
-
2014
- 2014-09-04 SG SG11201601066VA patent/SG11201601066VA/en unknown
- 2014-09-04 PE PE2016000323A patent/PE20160880A1/es not_active Application Discontinuation
- 2014-09-04 JP JP2016540386A patent/JP2016529311A/ja active Pending
- 2014-09-04 CA CA2921420A patent/CA2921420A1/en not_active Abandoned
- 2014-09-04 CN CN201480048882.7A patent/CN105579440A/zh active Pending
- 2014-09-04 WO PCT/US2014/054108 patent/WO2015035059A1/en not_active Ceased
- 2014-09-04 AU AU2014315151A patent/AU2014315151A1/en not_active Abandoned
- 2014-09-04 US US14/916,860 patent/US9776976B2/en not_active Expired - Fee Related
- 2014-09-04 MX MX2016002795A patent/MX2016002795A/es unknown
- 2014-09-04 EP EP14842357.7A patent/EP3041826A4/en not_active Withdrawn
- 2014-09-04 KR KR1020167008627A patent/KR20160048988A/ko not_active Withdrawn
- 2014-09-04 EA EA201690230A patent/EA201690230A1/ru unknown
-
2016
- 2016-03-02 IL IL244383A patent/IL244383A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2016529311A (ja) | 2016-09-23 |
| SG11201601066VA (en) | 2016-03-30 |
| US20160194292A1 (en) | 2016-07-07 |
| AU2014315151A1 (en) | 2016-03-03 |
| PE20160880A1 (es) | 2016-09-22 |
| US9776976B2 (en) | 2017-10-03 |
| EA201690230A1 (ru) | 2016-07-29 |
| KR20160048988A (ko) | 2016-05-04 |
| CN105579440A (zh) | 2016-05-11 |
| EP3041826A4 (en) | 2017-02-15 |
| IL244383A0 (en) | 2016-04-21 |
| WO2015035059A1 (en) | 2015-03-12 |
| CA2921420A1 (en) | 2015-03-12 |
| EP3041826A1 (en) | 2016-07-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2016002795A (es) | Compuestos de triazolona y usos de los mismos. | |
| NZ722345A (en) | Pyrazolone compounds and uses thereof | |
| CY1124793T1 (el) | Ακρυλαμιδια πυρρολο[2,3-d]πυριμιδινυλιου, πυρρολo[2,3-β]πυραζινυλιου και πυρρολο[2,3-d]πυριδινυλιου | |
| PH12017500276A1 (en) | Aminopyrimidinyl compounds as jak inhibitors | |
| CY1119714T1 (el) | Ενωσεις αναστολεων | |
| MX368703B (es) | Un inhibidor de mdm2 derivado de acido benzoico para el tratamiento del cancer. | |
| MY196749A (en) | Eif4a-inhibiting compounds and methods related thereto | |
| TR201906470T4 (tr) | İmmünomodülatörler. | |
| JOP20180009A1 (ar) | مركبات مثبط فيروس hiv | |
| PH12019500480A1 (en) | Pyridine compound | |
| BR112012027743A2 (pt) | ciclopropil dicarboxamidas e análogos exibindo atividades anticâncer e antiproliferativas | |
| PH12015501517A1 (en) | Pyrimidone derivatives and their use in the treatment, amelioration or prevention of a viral disease | |
| MX2016007311A (es) | Metodos para tratar canceres. | |
| SA515360469B1 (ar) | مركبات حلقية غير متجانسة لتثبيط إنزيم جلوتاميناز والطرق الخاصة باستخدامها | |
| MX352672B (es) | Compuestos heterocíclicos como inhibidores de mdm2 para el tratamiento del cáncer. | |
| MX2015012432A (es) | Inhibidores piridinicos de la cinasa cdk9. | |
| EA201690322A1 (ru) | Терапевтически активные соединения и способы их применения | |
| EA201591301A1 (ru) | Новые пиримидиновые и пиридиновые соединения и их применение | |
| NZ726365A (en) | Combinations for treating cancers | |
| EA201692542A1 (ru) | Индановые и индолиновые производные и их применение в качестве активаторов растворимой гуанилатциклазы | |
| EA027986B9 (ru) | Соединения триазолона и их применение | |
| MX2015010619A (es) | Cis-morfolinona y otros compuestos como inhibidores de mdm2 para el tratamiento del cancer. | |
| EA201591649A1 (ru) | Составы с органическими соединениями | |
| MX2015008288A (es) | Derivados de piridona y su uso en el tratamiento, mejora o prevencion de una enfermedad viral. | |
| EA201891239A1 (ru) | 1,3,4-тиадиазольные соединения и их применение в лечении рака |